0.14
0.14 (0%)
As of Jun 03, 2024
Galera Therapeutics, Inc. [GRTX]
Source:
Company Overview
Galera Therapeutics, Inc. is a biopharmaceutical company that since its inception has been developing a portfolio of small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, primarily by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM).
| Country | United States |
| Headquarters | malvern, pennsylvania |
| Phone Number | 610-725-1500 |
| Industry | manufacturing |
| CEO | J. Mel Sorensen, M.D. |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-20.2 |
| Net Income | $-19 |
| Net Cash | $-10 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -104.6% |
| Profit as % of Stockholder Equity | 12.8% |
Management Effectiveness
| Return on Equity | 12.8% |
| Return on Assets | -187.7% |
| Turnover Ratio | |
| EBITA | $-20.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $10.1 |
| Total Liabilities | $153.8 |
| Operating Cash Flow | $-12.1 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $2.2 |
